Nicholas Haft insider trades: Finch Therapeutics Group (FNCH) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nicholas reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | FNCH | ↑ Buy | 63,850 | $10.18 | $650K | Indirect | Dec 22, 2021 (2d) |
| Mar 23, 2021 | FNCH | ↑ Buy | 882,351 | $17.00 | $15.0M | Indirect | Mar 25, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Nicholas Haft's insider trades
Nicholas Haft is a director at Finch Therapeutics Group (FNCH). Since Mar 23, 2021, Nicholas has reported 2 open-market purchases worth $15.6M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (2 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every FNCH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.